
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12087251/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovascular Intervention and Therapeutics, 2022, 37, 1-34.	2.3	62
2	Renal denervation: basic and clinical evidence. Hypertension Research, 2022, 45, 198-209.	2.7	35
3	Malnutrition, hemodynamics and inflammation in heart failure with reduced, mildly reduced and preserved ejection fraction. Heart and Vessels, 2022, , .	1.2	3
4	Impact of hemodialysis on clinical and angiographic outcomes in in-stent restenotic lesions following optical coherence tomography-guided drug-coated balloon treatment. Cardiovascular Intervention and Therapeutics, 2021, 36, 429-435.	2.3	3
5	Mechanisms of drug-eluting stent restenosis. Cardiovascular Intervention and Therapeutics, 2021, 36, 23-29.	2.3	44
6	Prognostic impact of arterial stiffness following transcatheter aortic valve replacement. Journal of Cardiology, 2021, 78, 37-43.	1.9	7
7	Proximal optimisation technique versus final kissing balloon inflation in coronary bifurcation lesions: the randomised, multicentre PROPOT trial. EuroIntervention, 2021, 17, 747-756.	3.2	16
8	Clinical Predictors of Coronary Artery Plaque Progression by Quantitative Serial Assessment Using 320-Row Computed Tomography Coronary Angiography in Asymptomatic Patients with Type 2 Diabetes Mellitus. Journal of Cardiology, 2020, 76, 378-384.	1.9	2
9	Clinical expert consensus document on quantitative coronary angiography from the Japanese Association of Cardiovascular Intervention and Therapeutics. Cardiovascular Intervention and Therapeutics, 2020, 35, 105-116.	2.3	63
10	Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL) Tj ETQq(1444-1451.	0 0 0 rgBT /0 13.7	Overlock 10 T 351
11	Renal Denervation in Asia. Hypertension, 2020, 75, 590-602.	2.7	50
12	Effect of combination of non-slip element balloon and drug-coating balloon for in-stent restenosis lesions (ELEGANT study). Journal of Cardiology, 2019, 74, 436-442.	1.9	9
13	Impact of Residual Stenosis on the Angiographic Edge Restenosis of a Second-Generation Drug-Eluting Stent. International Heart Journal, 2019, 60, 1050-1060.	1.0	4
14	Impact of abdominal fat distribution, visceral fat, and subcutaneous fat on coronary plaque scores assessed by 320-row computed tomography coronary angiography. Atherosclerosis, 2019, 287, 155-161.	0.8	23
15	Association of onset-season with characteristics and long-term outcomes in acute myocardial infarction patients: results from the Japanese registry of acute myocardial infarction diagnosed by universal definition (J-MINUET) substudy. Heart and Vessels, 2019, 34, 1899-1908.	1.2	6
16	Evaluation of objective nutritional indexes as predictors of one-year outcomes after transcatheter aortic valve implantation. Journal of Cardiology, 2019, 74, 34-39.	1.9	32
17	Five-year clinical outcomes of everolimus-eluting stents from the post marketing study of CoCr-EES (XIENCE V/PROMUS) in Japan. Cardiovascular Intervention and Therapeutics, 2019, 34, 40-46.	2.3	17
18	Impact of stent type and prolonged dual antiplatelet therapy on long-term clinical outcomes in hemodialysis patients with coronary artery disease. Cardiovascular Intervention and Therapeutics, 2018, 33, 84-94.	2.3	8

#	Article	IF	CITATIONS
19	The impact of coronary calcification on angiographic and 3-year clinical outcomes of everolimus-eluting stents: results of a XIENCE V/PROMUS post-marketing surveillance study. Cardiovascular Intervention and Therapeutics, 2018, 33, 313-320.	2.3	12
20	Hemodynamic correlates of nutritional indexes in heart failure. Journal of Cardiology, 2018, 71, 557-563.	1.9	12
21	Prognostic Impact of Computed Tomography-Derived Abdominal Fat Area on Transcatheter Aortic Valve Implantation. Circulation Journal, 2018, 82, 3082-3089.	1.6	11
22	Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet, The, 2018, 391, 2346-2355.	13.7	597
23	Impact of Serum Phosphorus Levels on Outcomes After Implantation of Drug-Eluting Stents in Patients on Hemodialysis. Circulation Journal, 2018, 82, 388-395.	1.6	3
24	Relative atherosclerotic plaque volume by CT coronary angiography trumps conventional stenosis assessment for identifying flow-limiting lesions. International Journal of Cardiovascular Imaging, 2017, 33, 1847-1855.	1.5	5
25	Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet, The, 2017, 390, 2160-2170.	13.7	597
26	Cardiovascular Disease in Patients with End-Stage Renal Disease on Hemodialysis. Annals of Vascular Diseases, 2017, 10, 327-337.	0.5	29
27	Association of Dyslipidemia and Sex With Coronary Artery Calcium Assessed by Coronary Computed Tomography Angiography. International Heart Journal, 2017, 58, 695-703.	1.0	7
28	Three-Year Clinical Outcomes of Everolimus-Eluting Stents From the Post-Marketing Surveillance Study of Cobalt-Chromium Everolimus-Eluting Stent (XIENCE V/PROMUS) in Japan. Circulation Journal, 2016, 80, 906-912.	1.6	31
29	Intravascular ultrasound-guided chronic total occlusion wiring technique using 6 Fr catheters via bilateral transradial approach. Cardiovascular Intervention and Therapeutics, 2015, 30, 68-71.	2.3	7
30	Signet ring-like appearance: specific feature of vulnerable plaques detected by 320-slice multidetector computed tomography. EuroIntervention, 2014, 9, 1248-1248.	3.2	0
31	Angiographic findings of everolimus-eluting as compared to sirolimus-eluting stents: angiographic sub-study from the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial (RESET). Cardiovascular Intervention and Therapeutics, 2013, 28, 344-351.	2.3	24
32	Incidence and Predictors for Late Target Lesion Revascularization After Sirolimus-Eluting Stent Implantation. Circulation Journal, 2013, 77, 988-994.	1.6	10
33	Impact of Coronary Calcium on Outcome Following Sirolimus-Eluting Stent Implantation. American Journal of Cardiology, 2011, 108, 514-517.	1.6	18
34	Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents. Circulation, 2009, 119, 687-698.	1.6	172
35	Classification and Potential Mechanisms of Intravascular Ultrasound Patterns of Stent Fracture. American Journal of Cardiology, 2009, 103, 818-823.	1.6	90
36	Clinical and Angiographic Outcomes Following Percutaneous Coronary Intervention With Sirolimus-Eluting Stents Versus Bare-Metal Stents in Hemodialysis Patients. American Journal of Kidney Diseases, 2009, 54, 299-306.	1.9	40

#	Article	IF	CITATIONS
37	5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation. Journal of the American College of Cardiology, 2009, 54, 894-902.	2.8	142
38	Coronary Artery Aneurysms After Drug-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2008, 1, 14-21.	2.9	175
39	Chronic Arterial Responses to Overlapping Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2008, 1, 161-167.	2.9	9
40	Clinical Outcomes After Heterogeneous Overlap Stenting With Drug-Eluting Stents and Bare-Metal Stents for de Novo Coronary Artery Narrowings. American Journal of Cardiology, 2008, 101, 58-62.	1.6	162
41	Effectiveness of Drug-Eluting Stent Implantation for Patients With Unprotected Left Main Coronary Artery Stenosis. American Journal of Cardiology, 2008, 101, 801-806.	1.6	59
42	Impact of Mild or Moderate Renal Insufficiency on the Intravascular Ultrasonic Analysis of Chronic Vascular Response to Paclitaxel-Eluting and Bare-Metal Stents (from the TAXUS IV, V, and VI Trials). American Journal of Cardiology, 2008, 102, 1009-1016.	1.6	3
43	Efficacy of culprit plaque assessment by 64-slice multidetector computed tomography to predict transient no-reflow phenomenon during percutaneous coronary intervention. American Heart Journal, 2008, 155, 1150-1157.	2.7	75
44	Impact of Culprit Plaque Composition on the No-Reflow Phenomenon in Patients With Acute Coronary Syndrome An Intravascular Ultrasound Radiofrequency Analysis. Circulation Journal, 2008, 72, 1235-1241.	1.6	30
45	Sirolimus-Eluting Stents Suppress Neointimal Formation Irrespective of Metallic Allergy. Circulation Journal, 2008, 72, 893-896.	1.6	20
46	Relationship Between Coronary Artery Remodeling and Plaque Composition in Culprit Lesions An Intravascular Ultrasound Radiofrequency Analysis. Circulation Journal, 2007, 71, 654-660.	1.6	19
47	Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheterization and Cardiovascular Interventions, 2007, 69, 380-386.	1.7	179
48	Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents. Catheterization and Cardiovascular Interventions, 2007, 69, 808-814.	1.7	66
49	Sirolimus-Eluting Versus Paclitaxel-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Journal of the American College of Cardiology, 2006, 47, 507-514.	2.8	100
50	Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush―Technique. Journal of the American College of Cardiology, 2006, 47, 1949-1958.	2.8	228
51	Noncardiac Findings in Cardiac Imaging With Multidetector Computed Tomography. Journal of the American College of Cardiology, 2006, 48, 402-406.	2.8	201
52	Clinical and Angiographic Outcomes of Sirolimus-Eluting Stents Implantation in Japanese Patients in Daily Practice. Circulation Journal, 2006, 70, 1367-1371.	1.6	41
53	Sirolimusâ€Eluting Stent Implantation for Chronic Total Occlusion of the Left Main Coronary Artery. Journal of Interventional Cardiology, 2005, 18, 65-69.	1.2	7
	Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes of Sirolimus-Versus		

Comparison of Short- (One Month) and Long- (Twelve Months) Term Outcomes of Sirolimus- Versus Paclitaxel-Eluting Stents in 293 Consecutive Patients With Diabetes Mellitus (from the RESEARCH and) Tj ETQq0 0 ΩσgBT /Owerlock 10

#	Article	IF	CITATIONS
55	Geometrical validation of intravascular ultrasound radiofrequency data analysis (Virtual Histology) acquired with a 30 MHz boston scientific corporation imaging catheter. Catheterization and Cardiovascular Interventions, 2005, 66, 514-518.	1.7	21
56	Peristent Remodeling and Neointimal Suppression 2 Years After Polymer-Based, Paclitaxel-Eluting Stent Implantation. Circulation, 2005, 112, 3876-3883.	1.6	96
57	Short- and Long-Term Clinical Outcome After Drug-Eluting Stent Implantation for the Percutaneous Treatment of Left Main Coronary Artery Disease. Circulation, 2005, 111, 1383-1389.	1.6	305
58	Five year clinical effect of coronary stenting and coronary artery bypass grafting in renal insufficient patients with multivessel coronary artery disease: insights from ARTS trial. European Heart Journal, 2005, 26, 1488-1493.	2.2	63
59	Percutaneous therapy of bifurcation lesions with drugâ€eluting stent implantation: the Culotte technique revisited. International Journal of Cardiovascular Interventions, 2005, 7, 36-40.	0.5	32
60	The impact of metallic allergy on stent implantation. International Journal of Cardiology, 2005, 104, 319-325.	1.7	77
61	"Full metal jacket―(stented length ≥64 mm) using drug-eluting stents for de novo coronary artery lesions. American Heart Journal, 2005, 150, 994-999.	2.7	74
62	Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. Journal of the American College of Cardiology, 2005, 45, 947-953.	2.8	413
63	The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population. Journal of the American College of Cardiology, 2005, 45, 1135-1141.	2.8	204
64	Endothelial Progenitor Cell Capture by Stents Coated With Antibody Against CD34. Journal of the American College of Cardiology, 2005, 45, 1574-1579.	2.8	510
65	Evaluation of Four-Year Coronary Artery Response After Sirolimus-Eluting Stent Implantation Using Serial Quantitative Intravascular Ultrasound and Computer-Assisted Grayscale Value Analysis for Plaque Composition in Event-Free Patients. Journal of the American College of Cardiology, 2005, 46, 1670-1676.	2.8	87
66	The efficacy of sirolimus-eluting stents versus bare metal stents for diabetic patients undergoing elective percutaneous coronary intervention. Journal of Invasive Cardiology, 2005, 17, 344-8.	0.4	1
67	One-year clinical outcome of various doses and pharmacokinetic release formulations of paclitaxel eluted from an erodable polymer - Insight in the Paclitaxel In-Stent Controlled Elution Study (PISCES). EuroIntervention, 2005, 1, 165-72.	3.2	14
68	Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. American Journal of Cardiology, 2004, 94, 115-118.	1.6	124
69	Comparison of three-year outcomes after coronary stenting versus coronary artery bypass grafting in patients with multivessel coronary disease, including involvement of the left anterior descending coronary artery proximally (a subanalysis of the arterial revascularization therapies study trial). American lournal of Cardiology, 2004, 94, 627-631.	1.6	11
70	Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions. Journal of the American College of Cardiology, 2004, 43, 1954-1958.	2.8	194
71	Initial characterization of Ikari Guide catheter for transradial coronary intervention. Journal of Invasive Cardiology, 2004, 16, 65-8.	0.4	11
72	Treatment of coronary artery disease in dialysis patients with sirolimus-eluting stents: 1-year clinical follow-up of a consecutive series of cases. Journal of Invasive Cardiology, 2004, 16, 685-7.	0.4	9

#	Article	IF	CITATIONS
73	Clinical Outcome of Percutaneous Transluminal Coronary Rotational Atherectomy in Patients With End-Stage Renal Disease. Circulation Journal, 2003, 67, 617-621.	1.6	27
74	Coronary Revascularization Improves Long-Term Prognosis in Diabetic and Nondiabetic End-Stage Renal Disease Circulation Journal, 2002, 66, 595-599.	1.6	12